ChromoTek’s mission is to support extraordinary discoveries with high performing Nanobody-based affinity reagents in proteomics and cell biology. We strive to improve, accelerate, and simplify our customers’ research around the world.
ChromoTek pioneered the development and commercialization of Nanobody-based research reagents. ChromoTek created 2008 a missing link reagent between cell biology and proteomic applications, when it introduced the GFP-Trap® for immunoprecipitation. The outstanding performance of GFP-Trap drove the adoption of GFP as protein tag in biochemical applications.
We are utilizing the unique advantages of Nanobodies over conventional antibodies to develop new tools for better research:
- Nano-Traps affinity resins
- Nano-Booster and Nano-Label Nanobody dye conjugates
- Proprietary Chromobody® nanoprobes for live cell imaging
- Spot versatile capture and detection system
ChromoTek strives to improve the work of researchers worldwide with its reagents. In this process, every single one of our employees tries to work in a resource-friendly way. This ambition for greater sustainability is especially visible to our customers when they look at our packaging. For shipping, wherever possible, we use cardboard alternatives instead of plastic packaging and renewable raw materials instead of Styrofoam. You can find more information about our sustainable packaging materials here.
Chicago and Munich — October 15, 2020 — Proteintech, the benchmark in antibodies, today announces the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies.
ChromoTek is the market leader in nanobodies — high-performance recombinant reagents used for breakthrough research discoveries. The combined companies will better address the industry’s growing opportunities and challenges in single cell analysis, super resolution imaging, and multiplex assays.
“Our fit-for-purpose nanobody-based tools perfectly complement the comprehensive antibody coverage of the proteome that Proteintech offers,” said Dr. Marion Jung, CEO of ChromoTek. “It is exciting to be working together with a company that shares our common values in reproducibility and quality for the benefit of research and beyond.”
Dr. Jason Li, CEO of Proteintech said, “This new partnership will deliver considerable value to the market. With global manufacturing across three continents, not only will we serve the research market better, but we’ll also deeply impact translational science and therapeutic applications.”
About Proteintech Group
Proteintech, founded in 2002, is a leading manufacturer of antibodies, proteins and immunoassays. Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the human proteome. With over 70,000 publications and confirmed specificity, Proteintech offers antibodies and immunoassays across research areas. In addition, Proteintech produces cytokines, growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech sites are ISO13485 and ISO9001-2015 accredited. To learn more about Proteintech, please visit www.ptglab.com.